<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="The following regimens were administered based on international recommendations [17]:" exact="sofosbuvir" post="(SOF) plus ribavirin (RBV); SOF plus simeprevir (SMV) ± RBV; SOF"/>
 <result pre="were administered based on international recommendations [17]: sofosbuvir (SOF) plus" exact="ribavirin" post="(RBV); SOF plus simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV;"/>
 <result pre="international recommendations [17]: sofosbuvir (SOF) plus ribavirin (RBV); SOF plus" exact="simeprevir" post="(SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus daclatasvir (DCV) ± RBV;"/>
 <result pre="SOF plus simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus" exact="daclatasvir" post="(DCV) ± RBV; ombitasvir (OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV, glecaprevir (GLE) plus pibrentasvir"/>
 <result pre="simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus daclatasvir (DCV) ± RBV;" exact="ombitasvir" post="(OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV, glecaprevir (GLE) plus pibrentasvir (PIB), grazoprevir"/>
 <result pre="(83.3%) patients were in treatment with protease inhibitors: one with" exact="atazanavir" post="unboosted, two with lopinavir/ritonavir, two with darunavir/ritonavir. Of the"/>
 <result pre="sustained virological response after treatment with pegylated interferon α-2a and" exact="ribavirin" post="in patients infected with HCV genotypes 2 and 3PLoS"/>
</results>
